CNSP vs. DRMA, NTBL, SLRX, CYCC, CMND, QLGN, CYTO, LSDI, CWBR, and BPTH
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Dermata Therapeutics (DRMA), Notable Labs (NTBL), Salarius Pharmaceuticals (SLRX), Cyclacel Pharmaceuticals (CYCC), Clearmind Medicine (CMND), Qualigen Therapeutics (QLGN), Altamira Therapeutics (CYTO), Lucy Scientific Discovery (LSDI), CohBar (CWBR), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical preparations" industry.
CNS Pharmaceuticals (NASDAQ:CNSP) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.
CNS Pharmaceuticals received 42 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 70.77% of users gave CNS Pharmaceuticals an outperform vote while only 44.44% of users gave Dermata Therapeutics an outperform vote.
14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 3.9% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Dermata Therapeutics' return on equity of -107.95% beat CNS Pharmaceuticals' return on equity.
CNS Pharmaceuticals has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 1 mentions for Dermata Therapeutics. CNS Pharmaceuticals' average media sentiment score of 0.25 beat Dermata Therapeutics' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.
Dermata Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
CNS Pharmaceuticals beats Dermata Therapeutics on 7 of the 12 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
